Physician profile
Jonathan J Rasouli
NPI 1003172974
$92,515.85
in general payments reported to CMS, 2019-2025
32 companies · $7,151 in 2025
The $7,151 reported for 2025 was more than what 83% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,315 · 2020: $4,645 · 2021: $6,364 · 2022: $37K · 2023: $19K · 2024: $13K · 2025: $7,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $7,306 · Travel and Lodging: $5,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $26,950.00 |
| Food and Beverage | $7,305.83 |
| Travel and Lodging | $5,400.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $55,382.88 | 2019-2025 | Everest Spinal System, Cascadia Interbody System, N/A |
| Alphatec Spine, INC | $9,626.40 | 2022-2025 | Other - Miscellaneous, Lif, Biologics |
| Si-Bone, INC. | $6,035.81 | 2022-2023 | |
| Cerapedics INC. | $4,921.41 | 2021-2023 | I-Factor Peptide Enhanced Bone Graft |
| Zimmer Biomet Holdings, INC. | $2,306.35 | 2019 | |
| Surgalign Spine Technologies, INC. | $2,024.87 | 2021-2022 | |
| Centinel Spine, LLC | $1,657.04 | 2020-2021 | |
| Spineology INC. | $1,595.13 | 2022-2024 | Optimesh Expandable Interbody Fusion System |
| Medical Device Business Services, INC. | $1,557.75 | 2021 | |
| Nuvasive, INC. | $1,461.09 | 2019-2023 | Xlif, Tlx |
| Depuy Synthes Sales INC. | $1,194.56 | 2021-2025 | Teligen, Expedium, Confidence Spinal Cement System |
| Medtronic, INC. | $832.56 | 2021-2025 | Stealthstation S8 Platform, O-Arm |
| Synthes Gmbh | $819.41 | 2019 | |
| 4web, INC. | $481.03 | 2024-2025 | Spine Truss System |
| Arteriocyte Medical Systems, INC. | $398.15 | 2024 | Magellan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $342.90 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Augmedics INC. | $288.90 | 2022-2023 | Xvision |
| Vb Spine LLC | $215.57 | 2025 | Xia 3 System - Serrato |
| Zimvie INC. | $201.03 | 2022 | |
| Nevro Corp. | $192.85 | 2022 | |
| Intrinsic Therapeutics | $186.14 | 2022-2023 | Barricaid Acd (Annular Closure Device) |
| Ossdsign USA Incorporated | $153.92 | 2024-2025 | Ossdsign Catalyst |
| Lenoss Medical INC | $132.12 | 2024 | Access & Cavity Creation Kit |
| Abbott Laboratories | $105.95 | 2023 | Proclaim |
| Globus Medical, INC. | $92.36 | 2021-2025 | Xlif |
| Providence Medical Technology, INC. | $87.76 | 2024 | |
| Orthofix Medical, INC. | $67.47 | 2020 | |
| Sanara Medtech INC. | $42.03 | 2025 | Celleraterx |
| Medtronic USA, INC. | $40.89 | 2020 | |
| Misonix INC | $33.06 | 2019-2021 | |
| Spinal Simplicity, LLC | $21.41 | 2024 | Ha Minuteman G3-R |
| Penumbra, INC. | $17.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Rasouli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.